Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo. These findings suggest that at least at this dose combination, oral cannabinoids did not improve and may have disrupted objective sleep measures in insomnia patients. Larger controlled trials are needed before oral THC/CBD products can be recommended as reliable sleep aids for people with clinical insomnia.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-density EEG evidence characterizing how a commonly used THC/CBD combination affects sleep architecture in patients with diagnosed insomnia disorder, addressing a significant gap between clinical use and objective neurophysiological data. The findings establish baseline safety and efficacy parameters necessary for designing larger trials and informing evidence-based dosing recommendations for cannabinoid-based sleep interventions in clinical practice.
Methodological Considerations:
- Self-reported outcomes โ recall and social-desirability bias risk
Abstract: Cannabinoids, particularly ฮ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10โmg THC and 200โmg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5โmin, pโ=โ0.05, dโ=โ-0.5) with no change in wake after sleep onset (+10.7 min, pโ>โ0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9โmin, pโ<โ0.001, dโ=โ-1.5) and increased latency to REM sleep (+65.6โmin, pโ=โ0.008, dโ=โ0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, pโ=โ0.02, dโ=โ0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (โฅโ9โh post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
๐ด This pilot study provides a useful first look at how a fixed-ratio THC/CBD combination affects sleep architecture in insomnia patients using rigorous EEG methodology, yet several limitations warrant cautious interpretation. The small sample size of 20 participants, female predominance, single-dose design, and lack of detail on baseline cannabis exposure history limit generalizability and our ability to predict effects with repeated dosing or in more diverse populations. The specific 10:20 ratio tested may not reflect typical patient preferences or commercial formulations, and the absence of validated next-day cognitive or functional outcome measures leaves a critical gap regarding daytime consequences that often concern both patients and providers. That said, objective sleep architecture data from high-density EEG are more reliable than patient-reported sleep quality alone, making this work a reasonable foundation for larger trials. For now, clinicians should view cannabinoids as a potential option worth discussing with carefully selected insomnia patients who have failed or are intolerant of first-line agents, while emphasizing that